What BioNexus Gene Lab Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 5 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 516,128 | 516,128 |
| Disposed | 0 | 0 |
| Net activity | +516,128 | +516,128 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yap Chee Keong | Director | Aug 13 | Grant / award · A | +32,258 | — | — | 32,258 |
| Chong Set Fui | Chief Financial Officer | Aug 13 | Grant / award · A | +96,774 | — | — | 96,774 |
| Tan Lee Su-Leng | Chief Executive Officer | Aug 13 | Grant / award · A | +338,709 | — | — | 338,709 |
| Bin Abdul Hamid Muhammad Azrul | Director | Aug 13 | Grant / award · A | +32,258 | — | — | 32,258 |
| Low Jook Yuen | Director | Aug 13 | Grant / award · A | +16,129 | — | — | 17,390 |
Loading...
